News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Woundsource Reports On The Role Of NovaBay Pharmaceuticals, Inc. (NBY)’s Neutrophase® In Treatment Of ‘Flesh-Eating’ Infections



4/17/2014 9:50:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company, today announced that WoundSource™ has highlighted NovaBay’s NeutroPhase wound cleanser in a recent blog posting. The blog explains why NeutroPhase can play an important role in treating life-threatening necrotizing fasciitis, or ‘flesh-eating’ infections.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES